The theme of this meeting is “Knowledge Valorisation: Matching science and market needs”. We give the floor to the five Flemish universities, who will present you a global overview of their research activities related to the focus domains of Flanders Vaccine (vaccines & immunotherapeutics, prophylactic & curative). In addition, three specific “from research to valorisation” cases will be pitched per university. Our goal is to stimulate a dynamic interaction between academia & industry, hopefully giving rise to new partnerships. As an extra flavor, two online platforms, Academic Labs & BIPP will learn us how to facilitate in this.
Part I (Flanders Vaccine members only):
11:30 Registration & Welcome coffee
11:45 General Assembly Flanders Vaccine
12:45 Registration & welcome coffee
13:00 Intro R&D track, Hugo Van Heuverswyn, CEO Biomaric, Track lead R&D, BoD Flanders Vaccine
13:15 Intro Academic Labs Platform, Arne Smolders, Founder and Business Developer AcademicLabs
13:30 Intro Academia landscape, Sven Arnouts, Business Developer PROVAXS/UGhent & Chairman of Flanders Vaccine
13:35 2 VUB cases:
– Dr. Damya Laoui. Tumor-derived dendritic cells to slow tumor growth
– Prof. Tony Lahoutte.
13:50 General overview research at Hasselt University, Niels Hellings, Director BIOMED & Professor Immunology
14:00 UHasselt cases:
– Drs. Özgür Koc. Safety and immunogenicity of HBAI20 Hepatitis B vaccine in non-responding adults.
– Dr. Jeroen Bogie. The role of macrophages and microglia in multiple sclerosis.
– Dr. Patrick Vandormael. Discovery of novel diagnostic and theranostic autoantibodies for rheumatoid arthritis.
14:20 General overview research at University of Antwerp, Bruno Hoste, Research Manager Life Sciences
14:30 UAntwerp cases:
– Dr. Alex Vorsters. First void urine, a sample with big potential in HPV related research and clinical trials
– Prof. Heidi Theeten. Nasopharyngeal sample collection in infants for culture and molecular analysis
– Prof. Nathalie Cools. Cellular fingerprinting of the vaccine response using flow cytometry
14:50 Coffee break & Meet the pitchers
15:20 Intro BIP platform, Kristin Heirwegh, Product Manager BIPP
15:35 General overview research at Ghent University, Patrick Dhaese, Head Business Development – Life Sciences
15:45 UGhent cases:
– Drs. Tessa Vermeire. Recurrent mumps outbreaks: what are we facing and what can we do about it?
– Prof. Bruno De Geest. Engineering the immune system with synthetic nanomaterials.
– Prof. Eric Cox. Targeting of aminopeptidase N as oral immunisation strategy.
16:05 General overview research at Katholieke Universiteit Leuven, Ivo Roelants, IPR Officer K.U. Leuven LRD
16:15 3 KU Leuven cases:
– Prof. Johan Neyts. Pllav, a plasmid-based live-attenuated vaccine technology.
– Dr. Nick Geukens. DNA-based Antibody Therapy via In Vivo Electrotransfer.
– Prof. Eric Van Cutsem. Immunetherapy in gastrointestinal cancer.
16:35 Networking reception & Meet the pitchers
Registration (before April 12th, 2017):
– Flanders Vaccine members & students – 35 EUR (VAT excl.)
– Non-Flanders Vaccine members – 70 EUR (VAT excl.)
Apply for membership and attend this event at a reduced fee.
Registration cancellations received before April 4th, 2017 will be eligible for a refund. Cancellations received after this date will not be eligible for a refund.
Organiser: Flanders Vaccine with support of AcademicLabs & BIPP.